Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I wonder if the company will start doing pr now
Saint Tropez - it’s not quite that simple. The existing IDH business already covers all fixed costs, not true of many of the more speculative covid punts. That means that all the incremental gross margin made on additional business such as this falls straight to the bottom line. I suspect at the end of the day, any covid passport that is issued will need to be independently verified in a lab using accurate, tried and trusted equipment - IDH is an established player. 600 machines is a decent footprint, if more need to be built - that’s no bad thing for IDH.
some got decent profits here today
and holding still well up from this morning
nice way to finish the week
Reminds me of Ncyt worldwide distributers in place so I expect them to for Fda approval on this to sell in the Us
https://www.idsplc.com/worldwide/
All steps of the Test are automated with no manual reagent preparation required, ensuring minimal hands-on time for lab staff and a high daily throughput.
Yes it's a lab test.
lol 3.42 to sell £15k dont think so
why people spout off like that does my head in i wish you all well I honestly do but its a joke nobody knows what price its going to be
and offices
Strong cash position
https://www.lse.co.uk/rns/IDH/fy20-trading-update-ls1laez9k3328x5.html
Read the RNS it aint hard
or can peeps use it at home?
Crabtree ... £30m ? ...you are assuming that everyone in the supply chain worldwide works for nothing ! ..... I still say a good company but why the ramping hype ?
And they are already in NHS hospitals
LB2 there are about six hundred worldwide ..this is still a good company but I would say be careful to new investors ...avoid the hype do your own research !
This test could be a game changer for those that are eligible for immunity passports
If you have over a certain level of antibody
And imagine for research and data on covid pandemic
Why do certain individuals develop more antibody than others do
This is not just a yes or no test
It’s higher and bigger than that
read the RNS
600 labs have it and can produce 10k tests per month
6m per month at say £5 a test is £30m revenue - more labs will now also purchase this machine for this test so it will be more than 600 labs having this - some will have more than one
NT to buy at any stage for anything over 500
Lb2 read the rns
12 June 2020
Automated assay to detect SARS-CoV-2 antibodies
Immunodiagnostic Systems Holdings plc (IDS), a specialty solution provider to the clinical laboratory diagnostic market, announces a new automated COVID-19 IgG assay (The Test) has achieved CE marking and is expected to be available for sale by the end of this month.
The Test, which arises from the partnership between IDS and Technogenetics, is designed to run on the automated IDS-iSYS analyser. Today IDS and Technogenetics reached a commercial agreement under which IDS shall sell, market and support this Test on a global basis. For territories which do not accept CE marked products, the requisite regulatory approvals will be required.
Test Overview
· Detects specific IgG antibodies indicating past exposure to the COVID-19 virus and immune response;
· Quantitative test determines antibody concentration (titer), not just a 'yes/no' result;
· Highly accurate with a sensitivity of 100%1 and a specificity of 99.4%2, thus meeting the performance criteria specified by MHRA and the Royal College of Pathology, as well as the most common international performance requirements;
· Test results available within 25 minutes.
Unlike many COVID-19 serology assays currently available, this Test is a quantitative assay. It can determine the antibody concentration in patient serum, rather than giving a 'yes/no' result for prior exposure to the virus. Although the clinical level of functional immunity conferred by SARS-CoV-2 IgG antibodies has not yet been determined, we believe quantitative tests may ultimately be valuable in determining immunity status based on the levels of antibody in the blood.
All steps of the Test are automated with no manual reagent preparation required, ensuring minimal hands-on time for lab staff and a high daily throughput.
IDS-iSYS analysers are already installed in over six hundred laboratories worldwide, including many NHS hospitals. The majority of these analysers are in territories which use the CE mark as the basis for regulatory approval. Each system is capable of running over 10,000 tests per month.
Jaap Stuut, CEO of IDS commented
"We are pleased that our collaboration with Technogenetics has achieved the important milestone of CE-marking a quantitative, fully automated SARS-CoV-2 antibody test running on the IDS-iSYS analyser. We anticipate launching this assay throughout Europe later this month. IDS has increased production levels of its analysers, and we have sufficient inventory levels to facilitate higher analyser placement levels driven by new customers wishing to run the Test."
just went over 400p
LOL.....a sense a hint of jealousy, go back over to BRH it desperately needs you
https://invst.ly/r3veo first target 5.45
Yep think for covid research and vaccine development how important this is
How much demand there will be
!!!!
Immunity passports as well
Massive . Don’t let them shares go cheap folks
Like i said this will do a nasdaq type rise - 500%
the concentration of antibody is key